BRIEF-Janssen Says Erleada Oral Presentations Demonstrate Importance Of PSA As Key Efficacy Indicator And Show Strong Patient Adherence Rates

Reuters2021-09-12

Sept 11 (Reuters) - Johnson & Johnson :

* JANSSEN PHARMACEUTICAL - ERLEADA ORAL PRESENTATIONS DEMONSTRATE IMPORTANCE OF PSA AS KEY EFFICACY INDICATOR AND SHOW STRONG PATIENT ADHERENCE RATES

* JANSSEN PHARMACEUTICAL- POST-HOC ANALYSIS SHOWS ERLEADA PROVIDES RAPID, DEEP DURABLE PSA DECLINES IN ADVANCED PROSTATE CANCER

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Fayna
2021-09-12
Fayna
Interesting...

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2166370258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-12 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2166370258","market":"us","top_or_hot":-1,"title":"BRIEF-Janssen Says Erleada Oral Presentations Demonstrate Importance Of PSA As Key Efficacy Indicator And Show Strong Patient Adherence Rates","media":"Reuters","content":"<html><body><p>Sept 11 (Reuters) - Johnson &amp; Johnson   :</p><p>   * JANSSEN PHARMACEUTICAL - ERLEADA ORAL PRESENTATIONS DEMONSTRATE IMPORTANCE OF PSA AS KEY EFFICACY INDICATOR AND SHOW STRONG PATIENT ADHERENCE RATES</p><p>   * JANSSEN PHARMACEUTICAL- POST-HOC ANALYSIS SHOWS ERLEADA PROVIDES RAPID, DEEP DURABLE PSA DECLINES IN ADVANCED PROSTATE CANCER</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Janssen Says Erleada Oral Presentations Demonstrate Importance Of PSA As Key Efficacy Indicator And Show Strong Patient Adherence Rates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Janssen Says Erleada Oral Presentations Demonstrate Importance Of PSA As Key Efficacy Indicator And Show Strong Patient Adherence Rates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-12 08:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 11 (Reuters) - Johnson & Johnson   :   * JANSSEN PHARMACEUTICAL - ERLEADA ORAL PRESENTATIONS DEMONSTRATE IMPORTANCE OF PSA AS KEY EFFICACY INDICATOR AND SHOW STRONG PATIENT ADHERENCE RATES   * ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2166370258","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2166370258","pubTimestamp":1631405984,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 11 (Reuters) - Johnson & Johnson   :   * JANSSEN PHARMACEUTICAL - ERLEADA ORAL PRESENTATIONS DE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"Janssen说，Erleada的口头报告证明了PSA作为关键疗效指标的重要性，并显示了很强的患者坚持率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"Sept 11 (Reuters) - Johnson & Johnson   :   * JANSSEN PHARMACEUTICAL - ERLEADA ORAL PRESENTATIONS DEMONSTRATE IMPORTANCE OF PSA AS KEY EFFICACY INDICATOR AND SHOW STRONG PATIENT ADHERENCE RATES   * JANSSEN PHARMACEUTICAL- POST-HOC ANALYSIS SHOWS ERLEADA PROVIDES RAPID, DEEP DURABLE PSA DECLINES IN ADVANCED PROSTATE CANCERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":881746451,"gmtCreate":1631409528573,"gmtModify":1676530541872,"author":{"id":"3576151042223854","authorId":"3576151042223854","authorIdStr":"3576151042223854","name":"Fayna","avatar":"https://community-static.tradeup.com/news/04ea830c5237c9a4406b40ae311461e8","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3576151042223854"},"htmlText":"Interesting...","listText":"Interesting...","text":"Interesting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881746451","repostId":2166370258,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2166370258"}